Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $169.6 million.

  • Viridian Therapeutics, Inc.\DE's Cash & Equivalents fell 1531.07% to $169.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.6 million, marking a year-over-year decrease of 1531.07%. This contributed to the annual value of $99.6 million for FY2024, which is 314.41% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Cash & Equivalents stood at $169.6 million for Q3 2025, which was down 1531.07% from $117.3 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash & Equivalents peaked at $344.2 million during Q3 2022, and registered a low of $27.7 million during Q2 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $102.8 million (2023), whereas its average is $111.0 million.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Cash & Equivalents soared by 36170.09% in 2021 and then tumbled by 6757.88% in 2023.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Cash & Equivalents stood at $42.3 million in 2021, then surged by 267.81% to $155.6 million in 2022, then plummeted by 33.91% to $102.8 million in 2023, then dropped by 3.14% to $99.6 million in 2024, then surged by 70.34% to $169.6 million in 2025.
  • Its Cash & Equivalents was $169.6 million in Q3 2025, compared to $117.3 million in Q2 2025 and $116.2 million in Q1 2025.